SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Requiring Stater Month/Day/Yea	nent]				
		(Check all applicable) Director	10% Owne	r (M		ate of Original Filed		
		A below)	below)	Ap	plicable Line)	t/Group Filing (Check y One Reporting Person		
					Form filed b Reporting P	y More than One erson		
Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4) or Indirect (I) (Instr. 5)		t (D) (Ins	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
2. Date Exercisable and Expiration Date (Month/Day/Year)				or Exercise	se Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
Date Exercisable	Expiration Date	n Title	Amount or Number of Shares	Price of Derivative Security	Orrect (D) or Indirect (I) (Instr. 5)			
(1)	07/07/2021	Common Stock	37,037	14.4	D			
	Requiring Stater Month/Day/Yea 08/10/2016 Table I - Nor Table II - E g., puts, cal 2. Date Exerc Expiration Da (Month/Day/N Date Exercisable	Fable I - Non-Derivation Table II - Derivative g., puts, calls, warra 2. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date Date Exercisable Expiration Date	Requiring Statement Month/Day/Year) Medpace Holdings, Inc. 08/10/2016 4. Relationship of Reporting Perso (Check all applicable) Director X Officer (give title below) Sr. Vice President, C Fable I - Non-Derivative Securities Beneficially G., puts, calls, warrants, options, convertible 2. Amount of Securities Beneficially (Month/Day/Year) 3. Title and Amount of Securities (Month/Day/Year) Date Exercisable S. Title and Amount of Securities Check all applicable) Director 1. Title Title	Requiring Statement Month/Day/Year) Medpace Holdings, Inc. [MEDP Medpace Holdings, Inc. [Medpace Medpace Medpace Medpace Holdings, Inc. [Medpace Medpace Medpace Medpace Medpace Medpace Medpace Medpace Medpace Medpace <td>Requiring Statement Month/Day/Year) D8/10/2016 Medpace Holdings, Inc. [MEDP] Medpace Holdings, Inc. [MEDP] A. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Sr. Vice President, Operations 6.1 Fable I - Non-Derivative Securities Beneficially Owned Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nather (Instrement of the securities) Table II - Derivative Securities Beneficially Owned g., puts, calls, warrants, options, convertible securities) 4. Conversion or Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable 5. Title Amount of Shares 4. Conversion or Exercisable</td> <td>Requiring Statement Month/Day/Year) Medpace Holdings, Inc. [MEDP] Medpace Holdings, Inc. [MEDP] 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) 5. If Amendment, Day/Year) Director 10% Owner X Officer (give title below) Other (specify below) Sr. Vice President, Operations 6. Individual or Joint Applicable Line) X Form filed b Form filed b Reporting P Table I - Non-Derivative Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (I) (Instr. 5) 4. Nature of Indirect (Instr. 5) Table II - Derivative Securities Beneficially Owned g., puts, calls, warrants, options, convertible securities (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion of Exercise Price of Derivative Shares 5. Ownership Form: Date Date Expiration Date 1. Title Amount of Shares 5. Ownership Price (I) (Instr. 5)</td>	Requiring Statement Month/Day/Year) D8/10/2016 Medpace Holdings, Inc. [MEDP] Medpace Holdings, Inc. [MEDP] A. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Sr. Vice President, Operations 6.1 Fable I - Non-Derivative Securities Beneficially Owned Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nather (Instrement of the securities) Table II - Derivative Securities Beneficially Owned g., puts, calls, warrants, options, convertible securities) 4. Conversion or Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable 5. Title Amount of Shares 4. Conversion or Exercisable	Requiring Statement Month/Day/Year) Medpace Holdings, Inc. [MEDP] Medpace Holdings, Inc. [MEDP] 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) 5. If Amendment, Day/Year) Director 10% Owner X Officer (give title below) Other (specify below) Sr. Vice President, Operations 6. Individual or Joint Applicable Line) X Form filed b Form filed b Reporting P Table I - Non-Derivative Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (I) (Instr. 5) 4. Nature of Indirect (Instr. 5) Table II - Derivative Securities Beneficially Owned g., puts, calls, warrants, options, convertible securities (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion of Exercise Price of Derivative Shares 5. Ownership Form: Date Date Expiration Date 1. Title Amount of Shares 5. Ownership Price (I) (Instr. 5)		

Explanation of Responses:

1. The option vests in four equal annual installments over a four year period beginning on July 7, 2014.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

/s/ Stephen P. Ewald, Attorney-08/10/2016 in-Fact for Susan E. Burwig Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SECTION 16 POWER OF ATTORNEY SUSAN E. BURWIG

With respect to holdings of and transactions in securities issued by Medpace Holdings, Inc. (the "Company"), the undersigned hereby constitutes and appoints the officers of the Company listed on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;

2. execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in the discretion of such attorney-in-fact.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-facts substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is any Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14th day of June, 2016.

/s/ Susan E. Burwig Susan E. Burwig

Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

1.	Jesse J. Geiger	Chief Financial Officer
2.	Stephen P. Ewald	General Counsel and Corporate Secretary
3.	Todd Voelkerding	Executive Director, Finance